NEW YORK, May 1 - ProMetic BioSciences and Aldevron have expanded their collaboration to develop and market a new product that purifies gene-therapy and DNA-vaccine products, the firms said today.
The agreement, which began in 2000, brings together ProMetic's experience designing purification resins with Aldevron's knowledge of plasmid DNA manufacturing, according to the companies.
Aldevron currently uses ProMetic's Perflurosorb S to help it manufacture a West Nile Virus vaccine for the US Center for Disease Control and Prevention. Perflurosorb S is normally used to remove impurities from DNA solutions, said Prometic, which is a Canada-based wholly owned subsidiary of ProMetic Life Sciences.
The new collaboration aims at developing Perflurosorb S-based procedures that can be used to produce high-quality DNA for vaccines and gene-therapy applications.
"We have demonstrated that Perflurosorb S can be used to ... produce endotoxin-free plasmid DNA, [and] to separate different forms of DNA," said Michael Chambers, president and CEO of Aldevron. "The next step is to design reproducible procedures that can be used for any plasmid-DNA based product. This will represent a significant advancement in gene therapy manufacturing."
Through the alliance, Aldevron will develop for ProMetic the DNA purification procedures to be used with the Perflurosorb product line, the companies said. Aldevron will also help ProMetic promote and sell the resin.
Click here for more information.